MRI contrasting agent for contrasting cancer cell
US9765187B2 · kind B2 · utility
0Cited by
0References
1Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 27, 2015 |
| Grant date | Sep 19, 2017 |
| Priority date | — |
| Expiry date | Mar 27, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC08G69/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to MRI contrasting agent for contrasting cancer cell which contains ultrafine nanoparticles. More particularly, the present invention is directed to a self-assembled ligand composition comprising a ligand A, which is separated at a specific pH range, and a ligand B of which surface charge changes at a specific pH range, MRI contrast agent for contrasting cancer cell comprising said ligand composition and MRI contrasting nanoparticles, and the methods for preparing them.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.